| Abstract: | Advanced therapy medicinal products (ATMP s) represent the current pinnacle of ‘patient‐specific medicines’ and will change the nature of medicine in the near future. They fall into three categories; somatic cell‐therapy products, gene therapy products and cells or tissues for regenerative medicine, which are termed ‘tissue engineered’ products. The term also incorporates ‘combination products’ where a human cell or tissue is combined with a medical device. Plainly, many of these new medicines share similarities with conventional haematological stem cell transplant products and donor lymphocyte infusions as well as solid organ grafts and yet ATMP s are regulated as medicines and their development has remained predominantly in academic settings and within specialist centres. However, with the advent of commercialisation of dendritic cell vaccines, chimeric antigen receptor (CAR )‐T cells and genetically modified autologous haematopoietic stem cells to cure single gene‐defects in β‐thalassaemia and haemophilia, the widespread availability of these therapies needs to be accommodated. Uniquely to ATMP s, the patient or an allogeneic donor is regularly part of the manufacturing process. All of the examples given above require procurement of blood, bone marrow or an apheresate from a patient as a starting material for manufacture. This can only occur in a clinical facility licensed for the procurement of human cells for therapeutic use and this is likely to fall to haematology departments, either as stem cell transplant programmes or as blood transfusion departments, to provide under a contract with the company that will manufacture and supply the final medicine. The resource implications associated with this can impact on all haematology departments, not just stem cell transplant units, and should not be under‐estimated. |
